tuvatexib ointment (VDA-1102 ointment) / Vidac Pharma - LARVOL DELTA

VDA-CP-06 P2B: Clinical trial of VDA-1102 ointment for patients with actinic keratosis (clinicaltrialsregister.eu) - P1/2 | N=39 | Not yet recruiting | Sponsor: Vidac Pharma Ltd.

New P1/2 trial • Actinic Keratosis • Dermatology

VDA-CP-06 P2B: Clinical trial of VDA-1102 ointment for patients with actinic keratosis (clinicaltrialsregister.eu) - P1/2 | N=39 | Recruiting | Sponsor: Vidac Pharma Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Actinic Keratosis • Dermatology

Vidac Pharma receives US patent office Notice of Allowance for crucial compounds in its cancer drug candidates (GlobeNewswire) - "Vidac Pharma Holdings Plc...today announces it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) protecting a group of molecules and their ability to trigger an immune response across a wide range of cancers by detaching the Hexokinase-2 (HK2) enzyme from the mitochondrial VDAC pores. The molecules are the crucial compounds in Vidac’s two drug candidates, VDA-1102 and VDA-1275."

Patent • Cutaneous T-cell Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma (GlobeNewswire) - "Vidac Pharma Holdings Plc...announced it has received approval from the Helsinki Committee of the Beilinson Hospital in Israel to proceed with the second stage of a Phase 2a clinical trial of its lead drug candidate VDA-1102 in Mycosis Fungoides (MF), a form of Cutaneous T-Cell Lymphoma (CTCL). Having reported positive interim results based on 50% of subjects in January, the company now expects the second stage of the trial to take 3 to 4 months, and to be able to report final results in the fourth quarter of the year."

Trial status • Mycosis Fungoides

Vidac Pharma reports positive interim Phase 2a data in orphan disease cutaneous T-cell lymphoma (CTCL) with lead asset VDA-1102 (GlobeNewswire) - P2a | N=16 | "Vidac Pharma Holdings Plc....announces favorable findings from a Phase 2a interim analysis of its lead drug candidate VDA-1102 in Mycosis Fungoides (MF), a form of Cutaneous T-Cell Lymphoma (CTCL) and a rare 'orphan' disease which might command fast-track regulatory processing...The interim analysis of 50% of subjects showed an Objective Response Rate (ORR) of 56%, with 22% complete response (CR), and 34% partial response. Responses were observed between 8 and 12 weeks. These results compare favorably to the standard of care of mechlorethamine, which has a 13% CR and a much longer median response time of 26 weeks...All patients recovered, however, and the disease did not progress in any of the patients during the 4 months of the study....Next milestones are full-population interim results, expected in the second quarter, and final results in Q4."

P2a data • Mycosis Fungoides